MARKET

GWPH

GWPH

GW Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

125.35
-0.84
-0.67%
After Hours: 125.35 0 0.00% 19:59 07/02 EDT
OPEN
127.50
PREV CLOSE
126.19
HIGH
127.77
LOW
124.26
VOLUME
271.06K
TURNOVER
--
52 WEEK HIGH
180.75
52 WEEK LOW
67.98
MARKET CAP
3.90B
P/E (TTM)
121.46
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GWPH stock price target is 190.56 with a high estimate of 275.00 and a low estimate of 150.00.

EPS

GWPH News

More
GW Pharmaceuticals (GWPH) Nabiximols U.S. Development Program and Market Opportunity - Slideshow
Seeking Alpha - Article · 3d ago
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.
Benzinga · 3d ago
Top Marijuana Stocks on the NASDAQ for July 2020
Investopedia · 4d ago
Is GW Pharmaceuticals Stock a Buy?
You might pick pot producers, companies with just slight exposure to the industry, or medical marijuana stocks. The stock's been producing some impressive sales numbers over the past year, but for risk-averse investors, it may be too dependent on the success
Motley Fool · 4d ago
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
GlobeNewswire · 4d ago
GW Pharma updates plan to commercialize nabiximols in U.S.
Seeking Alpha - Article · 4d ago
GW Pharmaceuticals Presents Nabiximols US Development And Commercial Strategy
- Potential accelerated pathway to NDA submission - - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 - - Webcast featuring a range of guest speakers to be held
Potential accelerated pathway to NDA submission - - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 - - Webcast featuring a range of guest speakers to be held · 4d ago
Zogenix Fintepla Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 5d ago

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About GWPH

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.
More

Webull offers kinds of GW Pharmaceuticals PLC- ADR stock information, including NASDAQ:GWPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GWPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GWPH stock methods without spending real money on the virtual paper trading platform.